TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05623020: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN

Sponsor: Pfizer · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1060 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,299,828

Rescue Site Savings

+$6,822,816

Unlock Full NCT05623020 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05623020 Rescue Dossier →